Urologix v. ProstaLund
This article was originally published in The Gray Sheet
Motion for preliminary injunction against sales of ProstaLund's CoreTherm microwave thermotherapy system for benign prostatic hyperplasia is denied by Milwaukee federal court Judge Lynn Adelman, clearing the way for U.S. marketing, pending PMA approval "in the near future," ProstaLund says. Adelman also rules that one of two Urologix patents asserted against ProstaLund is invalid. ACMI will distribute the device...
You may also be interested in...
ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.